# Tioga Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tioga-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.tiogapharma.com
- Total disclosed funding: $52M
- Latest round: Series B (Apr 12, 2012)
- Investors on record: 5

## About

Tioga Pharmaceuticals is focused on developing therapeutic solutions to address unmet medical needs in gastrointestinal diseases, particularly through innovative treatments for inflammatory bowel disease and ulcerative colitis.Founded in 2005, Tioga Pharmaceuticals operates from San Diego, US, where it specializes in developing therapeutic solutions for gastrointestinal diseases. The company has successfully raised a total of USD 10.00 mn in funding, including a Series B round led by Thomas, McNerney & Partners in April 2012. Tioga has completed six deals to date.Tioga Pharmaceuticals specializes in developing innovative therapeutic solutions for unmet medical needs in the gastrointestinal disease market. Their products focus on novel formulations aimed at treating conditions like inflammatory bowel disease (IBD) and ulcerative colitis, targeting inflammatory processes and restoring mucosal health for improved patient quality of life. They cater to healthcare providers, hospitals, and specialty pharmacies, ensuring their products reach patients needing effective management of gastrointestinal disorders, primarily in North America and select international markets.Tioga Pharmaceuticals generates revenue through strategic partnerships and direct sales to healthcare facilities and specialty pharmacies. The company's sales typically follow a B2B model, providing products directly to hospitals and clinics, which then treat patients. Their pricing structures reflect the efficacy of flagship products, enhancing patient outcomes. Revenue streams are supplemented by collaborations with healthcare providers that may involve subscription models or bundled pricing for comprehensive care solutions.Tioga Pharmaceuticals aims to expand its market presence by designing and launching new therapeutic products targeting gastrointestinal diseases. The recent Series B funding of USD 10.00 mn will support these initiatives, particularly focusing on product development and market expansion. The company plans to penetrate additional geographic regions with high prevalence rates of gastrointestinal diseases, ensuring broader accessibility to its innovative treatments.

## Funding rounds

- Series B, Apr 12, 2012, $10M — Thomas, McNerney & Partners, Genesys Capital Management
- Series B, Dec 17, 2010, $18M — Forward Ventures, Genesys Capital Management, BB Biotech, New Leaf Venture Partners
- Series A, Jan 9, 2006, $24M — Forward Ventures, BB Biotech, New Leaf Venture Partners

## Investors

- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series A, Series B
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series A, Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series A, Series B
- Genesys Capital Management (https://capitalatlas.ai/funds/genesys-capital-management) — Series B
- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series B